ZimVie (NASDAQ:ZIMV) Upgraded to "Equal Weight" at Barclays

ZimVie (NASDAQ:ZIMV - Get Free Report) was upgraded by investment analysts at Barclays from an "underweight" rating to an "equal weight" rating in a research report issued on Tuesday. The firm currently has a $19.00 target price on the stock. Barclays's price objective indicates a potential upside of 1.25% from the stock's current price.

ZIMV has been the subject of several other research reports. B. Riley began coverage on ZimVie in a research report on Thursday, April 10th. They set a "buy" rating and a $16.00 price objective for the company. Needham & Company LLC restated a "hold" rating on shares of ZimVie in a report on Wednesday, April 9th. Wall Street Zen lowered ZimVie from a "strong-buy" rating to a "buy" rating in a research note on Friday. Finally, UBS Group lowered their price target on ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a report on Thursday, May 15th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $17.00.

ZimVie Stock Up 0.0%

Shares of ZIMV stock traded up $0.01 during trading hours on Tuesday, reaching $18.77. 983,970 shares of the company's stock were exchanged, compared to its average volume of 223,423. The stock's 50 day moving average is $9.05 and its 200-day moving average is $10.90. The company has a market cap of $522.61 million, a price-to-earnings ratio of -26.43 and a beta of 2.07. The company has a current ratio of 2.14, a quick ratio of 1.48 and a debt-to-equity ratio of 0.58. ZimVie has a fifty-two week low of $8.15 and a fifty-two week high of $22.18.

ZimVie (NASDAQ:ZIMV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.06. ZimVie had a negative net margin of 4.40% and a positive return on equity of 5.53%. The firm had revenue of $112.00 million for the quarter, compared to the consensus estimate of $113.10 million. Analysts predict that ZimVie will post 0.6 earnings per share for the current fiscal year.

Institutional Trading of ZimVie

Several hedge funds have recently added to or reduced their stakes in ZIMV. Wealth Enhancement Advisory Services LLC grew its position in ZimVie by 5.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,127 shares of the company's stock worth $211,000 after buying an additional 836 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of ZimVie by 4.2% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 42,000 shares of the company's stock valued at $454,000 after buying an additional 1,690 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of ZimVie by 8.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company's stock valued at $343,000 after buying an additional 1,852 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of ZimVie by 17.8% in the 4th quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock valued at $238,000 after buying an additional 2,569 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of ZimVie by 2.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 133,611 shares of the company's stock valued at $1,443,000 after buying an additional 3,043 shares in the last quarter. Institutional investors own 95.63% of the company's stock.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.